Estimation of efficiency and safety of use SGLT2 inhibitors and glucagon-like peptide agonists among patients with diabetes and cardiovascular disease in clinical practice
AbstractThis study is devoted to assessing the efficacy and safety of the use of drugs from the iNGLT-2 group and AR GLP-1 in the treatment of type 2 diabetes in patients with in patients with cardiovascular diseases (CVD) and the effect of the group of iNGLT-2 group and AR GLP-1 on the main risk factors for the development and progression of cardiac - vascular diseases. A retrospective analysis of data from inpatient cards from the Clinical Hospital named after with a diagnosis of type 2 diabetes at the age of 50 to 80 years, with a history of CVD. According to the results of the study, it was revealed that in the group of patients taking AR GGP-1, there was a more pronounced decrease in glycemia, weight, blood pressure compared with the group of patients taking iNGLT-2. While taking iNGLT-2, there was an increase in the left ventricular ejection fraction according to echocardiography and a decrease in symptoms of chronic heart failure.
Keywords:type 2 diabetes, SGLT2, AR GLP1, cardiovascular diseases
Funding. The study had no sponsor support.
Conflict of interests. The authors declare no conflict of interests.
For citation: Izmailova M.Ya., Demidova T.Yu., Gritskevich E.Yu. Estimation of efficiency and safety of use SGLT2 inhibitors and glucagon-like peptide agonists among patients with diabetes and cardiovascular disease in clinical practice. Endokrinologiya: novosti, mneniya, obuchenie [Endocrinology: News, Opinions, Training]. 2020; 9 (3): 71-2. DOI: https://doi.org/10.33029/2304-9529-2020-9-3-71-72 (in Russian)